Literature DB >> 9759851

Expression and function of CTLA-4 in Th1 and Th2 cells.

M L Alegre1, H Shiels, C B Thompson, T F Gajewski.   

Abstract

CTLA-4 is expressed on T cells after activation and shares homology with the CD28 costimulatory receptor. In contrast to CD28, CTLA-4 is thought to be a negative regulator of T cell activation. Cross-linking of CTLA-4 during activation of peripheral T cells reduces IL-2 production and arrests T cells in G1. Much less is known about the function of CTLA-4 in differentiated T cells. We have investigated the expression and function of CTLA-4 in established Th1 and Th2 clones and in bulk populations of Th1 and Th2 cells freshly derived in vitro from TCR transgenic splenocytes. We found that CTLA-4 was induced under similar conditions and with similar kinetics following activation of both Th1 and Th2 clones. However, CTLA-4 expression was much higher in Th2 than Th1 clones and lines. This was confirmed by flow cytometry, confocal microscopy, and Northern blot analysis. The ratio of surface to intracellular expression of CTLA-4 and its rate of endocytosis were similar in Th1 and Th2 clones. Inhibition of binding of CTLA-4 to its ligands using soluble anti-CTLA-4 mAb during stimulation with Ag increased the production not only of IL-2 by Th1 clones, but also that of IL-3 and IFN-gamma by Th1 clones and of IL-3, IL-4, IL-5, and IL-10 by Th2 clones. In contrast, when anti-CTLA-4 was coimmobilized with anti-CD3 and anti-CD28 mAbs, a decrease in the production of multiple cytokines was observed. We conclude that CTLA-4 can function to suppress the production of cytokines produced by both Th1 and Th2 cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759851

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Interaction between CTLA4 gene and IBD5 locus in Hungarian Crohn's disease patients.

Authors:  Veronika Csöngei; Luca Járomi; Eniko Sáfrány; Csilla Sipeky; Lili Magyari; Noémi Polgár; Judit Bene; Patrícia Sarlós; Lilla Lakner; Eszter Baricza; Melinda Szabó; Gábor Rappai; Béla Melegh
Journal:  Int J Colorectal Dis       Date:  2011-04-26       Impact factor: 2.571

Review 2.  Immunological decision-making: how does the immune system decide to mount a helper T-cell response?

Authors:  Gerard E Kaiko; Jay C Horvat; Kenneth W Beagley; Philip M Hansbro
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

3.  Surfactant protein D-mediated decrease of allergen-induced inflammation is dependent upon CTLA4.

Authors:  Ko-Wei Lin; Kai Yu Jen; Carlos Jose Suarez; Erika C Crouch; David L Perkins; Patricia W Finn
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

4.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Authors:  Jianjun Gao; Lewis Zhichang Shi; Hao Zhao; Jianfeng Chen; Liangwen Xiong; Qiuming He; Tenghui Chen; Jason Roszik; Chantale Bernatchez; Scott E Woodman; Pei-Ling Chen; Patrick Hwu; James P Allison; Andrew Futreal; Jennifer A Wargo; Padmanee Sharma
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

5.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors:  Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal:  J Invest Dermatol       Date:  2008-06-19       Impact factor: 8.551

Review 6.  Melanoma immunotherapy dominates the field.

Authors:  Panagiotis Diamantopoulos; Helen Gogas
Journal:  Ann Transl Med       Date:  2016-07

7.  CTLA-4 blockade: therapeutic potential in cancer treatments.

Authors:  Ahmad A Tarhini; Fatima Iqbal
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

Review 8.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

9.  Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Imelda S Quinlin; Khaliquzzaman A Samad; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Clin Immunol       Date:  2009-09-16       Impact factor: 3.969

10.  Astrocytes protect the CNS: antigen-specific T helper cell responses are inhibited by astrocyte-induced upregulation of CTLA-4 (CD152).

Authors:  Ulrike Gimsa; Anita ØRen; Pushpa Pandiyan; Daniela Teichmann; Ingo Bechmann; Robert Nitsch; Monika C Brunner-Weinzierl
Journal:  J Mol Med (Berl)       Date:  2004-03-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.